Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Vaccine tube

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website. 

  • Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
  • In the two different dose regimens vaccine efficacy was 90% in one and 62% in the other
  • Higher efficacy regimen used a halved first dose and standard second dose
  • Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections
  • There were no hospitalised or severe cases in anyone who received the vaccine
  • Large safety database from over 24,000 volunteers from clinical trials in the UK, Brazil and South Africa, with follow up since April
  • Crucially, vaccine can be easily administered in existing healthcare systems, stored at ‘fridge temperature’ (2-8 °C) and distributed using existing logistics
  • Large scale manufacturing ongoing in over 10 countries to support equitable global access

See more at https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine?hp

Similar stories

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

NDM student Romain Guyon awarded the 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Essential research by COI improves understanding of COVID

Since the start of the pandemic, the CAMS-Oxford Institute (COI) has carried out 11 projects to better understand COVID-19, resulting in 21 published research articles.

The University of Oxford signs MoU with Diamond Light Source

A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source, the UK’s national synchrotron has been agreed upon.

Sarah Gilbert awarded 2023 King Faisal Prize

Professor Dame Sarah Gilbert, the Saïd Chair of Vaccinology in the Nuffield Department of Medicine has been selected to receive King Faisal Prize for Medicine for 2023, along with Professor Dan Barouch of Harvard Medical School.

Three NDM researchers awarded Associate Professorships

We are delighted to announce that three researchers have been awarded the Associate Professor title, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.